Physician profile
Paul Michael Mann
NPI 1366447559
$37,642.28
in general payments reported to CMS, 2019-2025
33 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,288 · 2021: $7,540 · 2022: $20K · 2023: $2,728 · 2024: $1,830 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,105.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $12,959.80 | 2019-2025 | Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser, Clareon |
| Johnson & Johnson Vision Care, INC. | $12,607.45 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $3,794.08 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Allergan, INC. | $1,748.79 | 2019-2022 | |
| Abbvie INC. | $941.51 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $925.52 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $667.77 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $656.93 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $612.50 | 2021 | |
| Carl Zeiss Meditec, INC. | $311.82 | 2021 | |
| Amgen INC. | $297.88 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $277.33 | 2025 | Xdemvy |
| Sight Sciences, INC. | $222.84 | 2019-2025 | Tearcare System, Sion Surgical Instrument, Omni Surgical System |
| Biotissue Holdings INC. | $209.74 | 2019-2024 | |
| Dompe US, INC. | $185.11 | 2024-2025 | Oxervate |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $165.18 | 2025 | Kahook Dual Blade, Via360, Streamline |
| Carl Zeiss Meditec Cataract Technology INC. | $143.75 | 2023 | |
| Bausch & Lomb Americas INC. | $139.09 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.75 | 2019-2020 | |
| Glaukos Corporation | $119.90 | 2019-2022 | |
| Rxsight INC | $110.82 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Beaver-Visitec International, INC. | $90.38 | 2023 | |
| Harrow Eye, LLC | $64.30 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $47.11 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $35.98 | 2019 | |
| Astellas Pharma US INC | $34.97 | 2024 | Izervay |
| Lensar, INC. | $34.06 | 2023 | Lensar Laser System |
| Quidel Corporation | $31.90 | 2019 | |
| Kala Pharmaceuticals, INC. | $26.58 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $22.30 | 2019 | |
| Thea Pharma INC. | $19.07 | 2023 | Iyuzeh |
| Shire North American Group INC | $14.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.